A photo of Michael Grimley.

Michael S. Grimley, MD

  • Medical Director, Division of Bone Marrow Transplantation and Immune Deficiency
  • Professor, UC Department of Pediatrics
I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family.

About

Biography

I’ve been interested in medicine for as long as I can remember. My medical school experiences with the children solidified my feeling that pediatrics was the area I related to best.

Similarly, my exposure to pediatric and adult hematology/oncology patients and physicians in medical school confirmed that I wanted to work with these patients and colleagues.

As a bone marrow transplant physician, I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family.

My research involves finding treatments for and prevention of viral infections in immunocompromised patients.

When I’m not treating patients or involved in research, I enjoy spending time with my family.

MD: Emory University School of Medicine, Atlanta, GA, 1992.

Residency: Wilford Hall Medical Center, Lackland, AFB, TX, 1995.

Fellowship: Cincinnati Children’s Hospital Medical Center, 1999.

Certification: General Pediatrics, Pediatric Hematology/Oncology.

Licenses: Ohio, Texas.

Interests

Bone marrow transplantation for primary immunodeficiencies; cord blood transplants; leukemia

Services and Specialties

Cancer and Blood Diseases, Bone Marrow Transplantation BMT, Immune Deficiencies and Histiocytosis

Research Areas

Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases

Location

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease. Shah, NC; Bhoopatiraju, S; Abraham, A; Anderson, E; Andreansky, M; Bhatia, M; Chaudhury, S; Cuvelier, GD E; Godder, K; Grimley, M; et al. Transplantation and cellular therapy. 2021.

Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells. Holland, EM; Gonzalez, C; Levy, E; Valera, VA; Chalfin, H; Klicka-Skeels, J; Yates, B; Kleiner, DE; Hadigan, C; Dave, H; et al. Frontiers in Immunology. 2021; 12.

Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients. Rubinstein, JD; Jodele, S; Heyenbruch, D; Wilhelm, J; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; Keller, M; et al. Transplantation and cellular therapy. 2021.

Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. Qayed, M; Watkins, B; Gillespie, S; Bratrude, B; Betz, KM; Choi, SW; Davis, JH; Duncan, C; Giller, RH; Grimley, M; et al. Blood Advances. 2021.

Safety and Efficacy of Aru-1801 in Patients with Sickle Cell Disease: Early Results from the Phase 1/2 Momentum Study of a Modified Gamma Globin Gene Therapy and Reduced Intensity Conditioning. Grimley, M; Asnani, M; Shrestha, A; Felker, S; Lutzko, C; Arumugam, PI; Witting, S; Knight-Madden, J; Niss, O; Quinn, CT; et al. Blood. 2021; 138:3970-3970.

Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. Rubinstein, JD; Zhu, X; Leemhuis, T; Pham, G; Ray, L; Emberesh, S; Jodele, S; Thomas, S; Cancelas, JA; Bollard, CM; et al. Blood Advances. 2021; 5:3309-3321.

Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. Watkins, B; Qayed, M; McCracken, C; Bratrude, B; Betz, K; Suessmuth, Y; Yu, A; Sinclair, S; Furlan, S; Bosinger, S; et al. Journal of Clinical Oncology. 2021; 39:1865-1877.

Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. Danziger-Isakov, L; Khalil, N; Divanovic, A; Frenck, R; Grimley, M; Iliopoulos, I; Marsh, R; Paulsen, G; Phillips, CL; Schulert, G; et al. Pediatric Infectious Disease Journal. 2021; 40:e234-e235.

Incidence of thyroid dysfunction in children after HSCT with reduced intensity conditioning (RIC) or myeloablative conditioning (MAC). Wang, YZ M; Howell, JC; Grimley, MS; Lane, A; Davies, SM; Myers, KC. Pediatric Transplantation. 2021; 25.

Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa. Khandelwal, P; Yeh, RF; Yu, L; Lane, A; Dandoy, CE; El-Bietar, J; Davies, SM; Grimley, MS. Transplantation. 2021; 105:891-896.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey